The present study was performed to compare circulating levels of tumour necrosis factor-␣ (TNF␣) and plasma endothelin 1 (ET-1), of hypertensive patients with or without renal failure and with those of normotensive healthy subjects. The study population consisted of 21 healthy normotensive subjects and 22 hypertensive patients, 11 with essential hypertension, and 11 with hypertension and chronic renal failure (CRF).
Introduction
The pathogenesis of cardiovascular and renal diseases is associated with derangements of growth and differentiation of various cell types. In recent years the interest of researchers has focused on cytokines and growth factors as elements involved in the mechanisms responsible for the initiation and the progression of cardiovascular and glomerular injury. [1] [2] [3] Among those of particular interest are the tumour necrosis factor-␣ (TNF␣) and endothelin.
TNF␣ displays a number of effects in vitro that may affect the progression of glomerular injury. When TNF␣ is infused into the renal artery, glomerular endothelial damage ensues. 4 There is also evidence that TNF␣ may alter both glomerular haemodynamics and haemostatic balance, and induce glomerular infiltration by leukocytes. 5 TNF␣ is produced by a wide variety of cell types, mainly activated macrophages, in response to different exogenous and endogenous stimuli, and it is involved in several pathological conditions like glomerular diseases, 6, 7 diabetic glomerulopathy and chronic heart failure. 8, 9 Correspondence: Dr Santina Cottone Patients with hypertension manifested greater ET-1 levels than normotensive subjects (P Ͻ Ͻ Ͻ 0.01). Serum TNF␣ and ET-1 levels were higher in hypertensive patients with CRF than in patients with essential hypertension and normotensive subjects.
In the 22 hypertensive patients, TNF␣ levels were negatively correlated with serum creatinine (r = 0.60; P Ͻ Ͻ Ͻ 0.01), and ET-1 levels were positively correlated with UAE (r = 0.47, P Ͻ Ͻ Ͻ 0.05).
The present study has shown that hypertensive patients, and particularly those with renal insufficiency, manifest abnormal blood levels of ET-1 and TNF␣. These factors could contribute to both cardiovascular and renal damage.
Endothelial cells synthesise a pre-pro-endothelin, cleaved to form big endothelin. Endothelin-1 (ET-1) is one of three different isoforms deriving from the proteolytic processing of this specific pro-hormone. 10 Because of the vasoconstrictor potency and sustained action of ET-1 on the vasculature, it was hypothesised that this peptide may play an important role in hypertensive states. Some data also points to a role of ET-1 in the pathogenesis of glomerular injury. 11, 12 Nonetheless, data regarding plasma values of ET-1 in hypertensive subjects with both essential hypertension and renal parenchymal diseases, are still conflicting. [13] [14] [15] It has also been suggested that a potential increase in the expression of pre-pro-endothelin 1 constitutes one of the mechanisms implicated in TNF␣ glomerular haemodynamic effect. 16 The potential implication of TNF␣ in decreasing glomerular blood flow and filtration rate is explained by alterations in the balance between vasoconstrictive and vasodilating mediators. 5, 17, 18 In the present study, we have measured blood levels of TNF␣ and ET-1 in subjects with essential hypertension and subjects with hypertension and chronic renal insufficiency.
Subjects and methods
The study population consisted of 21 healthy normotensive (10 female and 11 male), and 22 hypertensive subjects. Of the 22 hypertensive subjects, 11 were affected by mild-to-moderate essential hypertension, and 11 by chronic renal failure due to a variety of renal diseases.
Hypertension was defined as elevated blood pressure obtained as a mean of three consecutive recordings while in a sitting position, exceeding 160/95 mm Hg. The diagnosis of primary hypertension was based on urinalysis, serum creatinine and creatinine clearance, 24-h urinary albumin excretion rate (UAE), serum and urinary electrolytes, plasma catecholamines, and abdominal echography.
Patients with essential hypertension and hypertensive patients with chronic renal failure (CRF) were studied after discontinuation of all anti-hypertensive drugs for at least 8 days. All subjects were given a diet containing approximately 100 mEq/day of sodium, and the compliance to it was verified by measuring urinary electrolytes. Before entering the study, all patients had been treated with diuretics and anti-adrenergic drugs.
On the morning before the study, at 08.00 am, after signing an informed consent, all subjects were hospitalised, a 24-h non-invasive ambulatory blood pressure monitoring (ABPM) and 24-h urine collection were initiated to measure urinary albumin excretion and/or proteinuria. The following morning, at 08.00 am and after fasting overnight, all subjects assumed the supine position for at least 1 h and blood samples were drawn from an antecubital vein to assay plasma levels of ET-1, TNF␣, and serum creatinine.
Blood samples for plasma ET-1 assay were collected in tubes containing EDTA, and stored at −15°C. The peptide was extracted from plasma using Amersham's Amprep C2 columns and assayed by ELISA (Amersham Kit: Amersham International, Little Chalfont, Bucks, UK). The ET-1 cross-reactivity with big ET was 0.07%. The sensitivity of the method was 5 fmol/ml, with a variation coefficient equal to 6.4%. Blood samples for TNF␣ were stored at −30°C until the assay. Serum TNF␣ was assayed by ELISA (Amersham Kit). The sensitivity of TNF␣ assay was 7.5 pg/ml, and the cross-reactivity with other cytokines was Ͻ5 pg/ml. Carrying out both the ELISA assays, in order to increase the specificity of the assay and to avoid interferences with other serum components a few contrivances according to de Kossodo 19 were used. Microalbuminuria was assayed by Bouty Ria Kit (Bouty, Sesto S Giovanni, Italy). The sensitivity was 0.4 mcg/min and the coefficient of variation Ͻ4%. Serum and urinary creatinine were assayed by spectrophotometry.
ABPM was carried out by Spacelabs 90207 (Redmond, WA, USA) and the data were analysed by SpaceLabs' software ABP PC interface, version 2.40.23.
Statistical analysis was carried out by the SISTAT DATA software package for the Macintosh, version 5.2. The 21 normotensives were compared with the entire group of 22 hypertensive patients or with the two groups of hypertensive patients with or without renal insufficiency.
Comparisons between the groups were done by analysis of variance and Student's t-test. Correlation analyses were performed by least-square linear regression analysis. Results are reported as mean ± s.e.m. excepting UAE which is reported as median and range interquartile.
Results
Serum levels of TNF␣ were significantly lower in normotensive subjects than in the whole group of 22 hypertensives (10 ± 0.8 vs 16 ± 1.6 pg/ml; P Ͻ 0.002). However, TNF␣ levels were greater in patients with CRF (P Ͻ 0.03) than in controls, but there was no difference in TNF␣ levels between patients with essential hypertension and controls ( Table 1 ).
The ET-1 levels were significantly greater in the 22 hypertensive patients than in healthy normotensive subjects (11.9 ± 1.1 vs 5.5 ± 0.29 fmol/ml; P Ͻ 0.0001), both in patients with essential hypertension and those with CRF.
In patients with essential hypertension, the mean blood pressure measured in the clinic (167 ± 3/2/106 ± 2. mm Hg) was no different than in patients with chronic renal insufficiency (173 ± 4/108 ± 3.6 mm Hg). However, 24-h systolic and diastolic blood pressures were significantly greater in patients with hypertension and chronic renal insufficiency than in those with essential hypertension (Table 1) .
In the whole group of 22 hypertensive patients there was a significant correlation between ET-1 levels and UAE (r = 0.47, P Ͻ 0.05) ( Figure 1) ; furthermore, TNF␣ levels were negatively correlated with creatinine clearance (r = −0.60; P Ͻ 0.01). There was no correlation between TNF␣ levels and 24-h blood pressure.
In patients with essential hypertension there was a significant correlation between TNF␣ levels and serum creatinine (r = 0.64; P Ͻ 0.05).
Discussion
The development and maintenance of hypertension is associated with functional and structural changes in the cardiovascular system characterised by vascular smooth muscle cell hypertrophy or replication and myocardial hypertrophy. Hypertension may also cause progressive glomerulosclerosis. 20, 21 In recent years, it has been postulated that growth factors may be involved in the pathophysiology of these structural derangements. 2, 22, 23 Several studies have shown that both platelet-derived and transforming growth factors, as well as TNF␣ may play a role in the pathogenesis of glomerular injury. 6, 7, 24, 25 TNF␣ enhances the expression of intercellular adhesion molecule-1 (ICAM-1) 9 and blood levels of ICAM-1 were found to be increased in atherosclerotic hypertensive subjects with preserved renal function, suggesting a systemic endothelial dysfunction. 26 Furthermore, on the basis of experimental results Liu et al 27, 28 hypothesised that in hypertension, vascular thrombotic risk is associated with Table 1 Mean age, serum creatinine and creatinine clearance (Clcr), blood levels of TNF␣ and ET-1, UAE, 24-h systolic-(SBP), diastolic (DBP) and mean (MBP) blood pressures in normotensive controls (NT), in patients with essential hypertension (EH), and in hypertensive subjects with renal insufficiency (CRF)
Age (years) 38 ± 4.7 41 ± 3.8 43 ± 6 Creatinine (mg/dl) 0.8 ± 0.03 0.9 ± 0.06 4.6 ± 0. increased endothelial adhesion and subendothelial accumulation of monocytes/macrophages, and with an augmented vascular capacity to produce cytokines such as TNF␣. Considering these reports, it seems that the determination of TNF␣ concentration in serum may be useful in studying a broad series of pathological states. However, depending upon the type of the assay used to determine cytokine concentrations, results between and within laboratories may differ significantly due to sensitivity as well as to crossreactivity. The WHO International Collaborative Study 19 showed good results by the ELISA method and made a number of suggestions aimed to validate the assay, therefore in our laboratory a few devices were made according to these recommendations.
In the present study, we have shown greater blood levels of TNF␣ in hypertensive patients with CRF than in normotensive healthy subjects and subjects with mild-to-moderate essential hypertension. Moreover, blood levels of TNF␣ were negatively correlated with creatinine clearance. This suggests a possible relationship between elevation of TNF␣ and glomerular injury in patients with hypertension and CRF.
Endothelin-1 is a potent vasoconstrictor that may also participate in the pathogenesis of hypertension. ET-1 is mainly released albuminally from the endothelium towards the underlying smooth muscle, and it is rapidly cleared from the circulation. In arterial hypertension high-to-low circulating values of ET-1 have been reported, 15, 29, 30 probably due to different methods of assay and different normal range, wideness of the population studied as well as different criteria of enrolment employed. Therefore, it is clear that there are a few difficulties in interpreting the significance of plasma ET-1 concentrations.
We observed higher levels of ET-1 in hypertensive patients than in normotensive individuals and even greater levels in hypertensive patients with CRF than those with essential hypertension. It is of interest that hypertensive patients with CRF also had higher 24-h blood pressure levels than patients with essential hypertension. This suggests that ET-1 may participate in the pathophysiology of hypertension. Alternatively, the greater levels of ET-1 in patients with CRF than in patients with essential hypertension and normotensive controls could be a reflection of greater endothelial injury caused by higher levels of blood pressure. On the other hand, it is to be considered that in CRF there could be a slower ET-1 clearance.
We also observed greater levels of UAE in hypertensive patients with CRF than in those with essential hypertension and normotensive controls. UAE was greater in patients with essential hypertension than in control subjects. We observed a significant correlation between levels of ET-1 and UAE in the entire group of hypertensive subjects. UAE is considered a marker of severity of glomerular injury both in patients with glomerulonephritis as well as in patients with essential hypertension. 31 Because experimental evidence indicates that ET-1 may participate in the genesis of glomerular injury, 11, 12 our data raises the possibility that ET-1 may participate in the pathogenesis of renal injury in hypertension. Alternatively, the increased levels of ET-1 may be the expression of end-organ damage rather than its cause.
